CompanyGraph
Abbott Laboratories
ABT · NYSE Arca · United States
Makes glucose sensors for diabetics that never need a fingerstick calibration because the factory does it for you.
Abbott Laboratories makes the FreeStyle Libre, a sensor that a diabetic patient wears on their arm for 14 days to track blood sugar without pricking their finger. That fingerstick-free guarantee is only possible because each sensor arrives from the factory with its glucose oxidase enzyme coating already measured and locked to a calibration standard — a step that happens on Abbott's own dedicated production lines because the enzyme chemistry and the calibration check cannot be separated without losing the accuracy that makes the product work. Every 14 days, every patient needs a new sensor, so the entire recurring revenue stream runs back through those same lines, and if a batch of enzyme coating falls outside its activity tolerance, that batch cannot ship at all — there is no quick fix because the calibration accuracy is built into the coating itself. Competitors cannot simply buy their way to the same result, because the knowledge of how to prepare the enzyme and verify each batch is embedded in years of accumulated process learning rather than in any equipment or ingredient that can be purchased.
How does this company make money?
Abbott sells the FreeStyle Libre sensor as a physical unit through prescription channels. Because each sensor lasts only 14 days, a patient with continuous glucose monitoring needs a new one roughly every two weeks all year long. That replacement cycle turns every active patient into a recurring source of revenue tied directly to the manufacturing process that produces each sensor.
What makes this company hard to replace?
Switching to a different glucose monitor is not simple for most users. FDA device interoperability standards require new 510(k) submissions before a different monitor can connect to an insulin pump, so patients who use pumps face a regulatory hurdle. Endocrinology practices have built their electronic medical record systems around FreeStyle Libre data formats specifically, meaning a switch breaks their workflows. Pharmacy benefit managers also negotiate formulary positions through multi-year exclusive contracts, so a competing device may simply not be covered.
What limits this company?
Every batch of sensors must hit a very narrow enzyme activity level to qualify as fingerstick-free. If a batch falls outside that range, it cannot ship. Because that activity level is batch-specific and cannot be fully automated, how many sensors Abbott can produce is ultimately limited by how many qualified enzyme preparation and calibration runs its facilities can complete — not by how fast robots can assemble the physical sensor.
What does this company depend on?
Abbott cannot run without glucose oxidase enzyme supplies for the sensor chemistry, Bluetooth Low Energy chips that transmit glucose readings continuously, FDA 510(k) clearance that allows the device to replace fingerstick readings, sterile manufacturing facilities certified to ISO 13485 standards, and pharmacy benefit manager formulary inclusion so that prescriptions are covered for patients.
Who depends on this company?
Type 1 diabetics rely on the continuous glucose data to make insulin dosing decisions — without it, they would be back to manual fingerstick testing. Endocrinology practices have built remote patient monitoring protocols around the sensor's data streams, and those protocols would fail if the data stopped. Diabetes management apps that pull data through the FreeStyle Libre API would also lose their core input.
How does this company scale?
Once the enzyme coating process is established at a manufacturing site, Abbott can replicate that site to grow production. What does not get easier as the company grows is the enzyme preparation and calibration chemistry itself — it still requires specialized quality control on every batch because sensor accuracy depends on that batch-specific enzyme activity level, and no amount of automation removes that check.
What external forces can significantly affect this company?
Medicare reimbursement rate changes can directly affect how many patients can afford continuous glucose monitors through insurance coverage. Global semiconductor shortages can limit the supply of Bluetooth Low Energy chips needed to build each sensor. In Europe, GDPR requirements govern how health data collected from the wearable sensors can be stored and used.
Where is this company structurally vulnerable?
If the glucose oxidase enzyme supply became contaminated or a qualified supplier was lost, Abbott would have to reformulate the enzyme coating. That reformulation would invalidate the calibration tolerances already approved in existing FDA 510(k) clearances, forcing new FDA submissions before the sensor could ship again. The very process learning that makes the product hard to copy is also what makes a forced reformulation a regulatory restart, not a quick fix.